DEF: Inogen Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals

Inogen announces its annual stockholders meeting to be held virtually on May 14, 2025, featuring proposals including director elections, auditor ratification, executive compensation, and equity incentive plan approval.

Summary

• Inogen, Inc. will hold its Annual Meeting of Stockholders virtually on May 14, 2025, at 10:00 a.m. Pacific Time.
• Stockholders of record as of March 17, 2025, are entitled to vote.
• The meeting will address the election of three Class II directors, ratification of Deloitte & Touche LLP as the independent auditor, an advisory vote on executive compensation, and approval of the Amended and Restated 2023 Equity Incentive Plan.
• The company expects to mail the Notice of Internet Availability of Proxy Materials on or about March 27, 2025.
• Stockholders are encouraged to vote via the Internet, telephone, or mail.

Sentiment

Score: 7

Explanation: The document is generally positive due to the improved financial performance metrics and the focus on aligning executive compensation with stockholder interests. However, the net loss and negative Adjusted EBITDA temper the overall sentiment.

Positives

• The company is providing electronic access to proxy materials to expedite receipt and lower costs.
• Stockholders have multiple options for voting, including Internet, telephone, and mail.
• The Board encourages stockholders to engage with management and has increased outreach efforts.
• The company has adopted a Clawback Policy that complies with the mandatory recovery of erroneously paid compensation rules of the Nasdaq Stock Market, applicable to our executive officers that provides for the recovery of incentive-based compensation in the event of a financial restatement under certain circumstances.

Negatives

• The company incurred a net loss of $35.9 million for 2024.
• The company incurred a non-GAAP Adjusted EBITDA of negative $9.5 million for 2024.

Risks

• If the Amended and Restated 2023 Equity Incentive Plan is not approved, the company may face challenges in attracting and retaining key personnel.
• The classification of the Board may delay or prevent changes in control of the company.
• The company faces risks related to strategic, financial, business and operational, legal and compliance, and reputational matters.

Future Outlook

The company anticipates that the shares available under the Amended and Restated Plan will be sufficient to meet expected needs through calendar year 2025 and expects to request additional shares at the 2026 annual meeting.

Management Comments

• Kevin R.M. Smith, Chief Executive Officer and President: 'On behalf of the Board of Directors, I would like to express our appreciation for your interest in Inogen.'

Industry Context

Inogen competes with other medical device and diagnostic companies for executive talent, and the compensation program is designed to be competitive within the industry.

Comparison to Industry Standards

• The Compensation Committee uses a peer group of 19 similarly-situated medical device and diagnostic companies to benchmark executive compensation.
• The peer group includes companies such as Alphatec Holdings, Inc, LeMaitre Vascular, Inc, AngioDynamics, Inc, Merit Medical Systems, Inc, Artivion, Inc, Nevro Corporation, AtriCure, Inc, OraSure Technologies, Inc, Avanos Medical, Inc, Orthofix Medical, Inc, Axonics, Inc, STAAR Surgical Company, CONMED Corporation, Tactile Systems Technology, Inc, Glaukos Corporation, Tandem Diabetes Care, Inc, iRhythm Technologies, Inc, Viemed Healthcare, Inc, and Zynex, Inc.

Management Changes

Stakeholder Impact

• Approval of the Amended and Restated 2023 Equity Incentive Plan is intended to align the interests of employees and stockholders.
• The executive compensation program is designed to drive company performance and increase stockholder returns.

Next Steps

• Stockholders are urged to submit their vote via the Internet, telephone or mail.
• The Board will consider the outcome of the advisory vote on executive compensation when making future compensation decisions.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Directors, Executive Compensation, Equity Incentive Plan, Deloitte & Touche LLP, Voting, Inogen